Role of Methotrexate in the Treatment of Chronic Cholestatic Disorders

Clinics in Liver Disease

Volumn 12, Issue 1, 2008, Pages 81-96

  Novak, Kerri ^a   Swain, Mark G ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; TACROLIMUS; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOCHEMISTRY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COUGHING; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; HUMAN; INTERSTITIAL PNEUMONIA; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA; OSTEOLYSIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

CHOLESTASIS; CHRONIC DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE;

EID: 38749148051     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.11.011     Document Type: Review

References (86)

1. O'Dell J.R. Methotrexate, leflunomide, and combination therapies. In: Harris Jr. E.D., Budd R.C., Genovese M.C., et al. (Eds). Kelley's textbook of rheumatology. 7th edition (2005), WB Saunders, Philadelphia 996-1042
2. Lipsky P.E., van der Heijde D.M., St Clair W.E., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 26 (2000) 27-29
3. Heydendael V.M.R., Spuls P.I., Opmeer B.C., et al. Methotrexate versus cyclosporine in moderate to severe chronic plaque psoriasis. N Engl J Med 349 (2003) 658-665
4. Alfadhi A.A.F., McDonal J.W.D., and Feagan B. Methotrexate for the induction of remission of refractory Crohn's disease. Cochrane Database Syst Rev 1 (2003) CD003459
5. Feagan B.G., Rochon J., Fedorak R.N., et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 332 (1995) 292-297
6. Cronstein B.N. The mechanism of action of methotrexate. Rheum Dis Clin North Am 23 4 (1997) 739-755
7. Barrera P., Haagsma C.J., Boerbooms A., et al. Effect of methotrexate alone or in combination with suphasalazine on the production and circulating concentrations of cytokines and their antagonists: longitudinal evaluation in patients with rheumatoid arthritis. Br J Rheumatol 34 8 (1995) 747-755
8. Pincus T., Yazici Y., Sokka T., et al. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 21 S31 (2003) S179-S185
9. Johnston A., Gudjonsson J.E., Sigmundsdottir H., et al. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 114 (2005) 154-163
10. Rudwaleit M., Yin Z., Siegaert S., et al. Response to methotrexate in early rheumatoid arthritis is associated with a decrease in T cell derived tumour necrosis factor-alpha, increase of interleukin 10 and predicted by the initial concentration of interleukin 4. Ann Rheum Dis 59 (2000) 311-314
11. Kraan M.C., Smeets T.J.M., and van Loon M.J. Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis (rheumatic disease research). Ann Rheum Dis 63 9 (2004) 1056-1066
12. Barsky H.E., Lea S.R., Preshaw P.M., et al. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Experim Immunol 149 (2007) 217-225
13. Zwerina J., Redlich K., Polzer K., et al. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A 104 28 (2007) 11742-11747
14. Neuman M., Angulo P., Malkiewicz I., et al. Tumor necrosis factor-α and transforming growth factor-β reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol 17 (2002) 196-202
15. Donaldson P., Agarwal K., and Craggs A. HLA and cirrhosis: associations with disease progression and disease susceptibility. GUT 48 (2001) 397-402
16. Miller L., and Dinarello C. Methotrexate inhibits IL-1 activity. Arthritis Rheum 29 (1986) S86
17. Miller L.C., Sharma A., McKusick A.F., et al. Synthesis of interleukin-1β in primary biliary cirrhosis: relationship to treatment with methotrexate or colchicines and disease progression. Hepatology 22 (1995) 518-524
18. La Montagna G., Tirri R., Vitello R., et al. Safety of methotrexate in rheumatoid arthritis: a retrospective cohort study in clinical practice. Rheumatism 58 4 (2006) 261-267
19. Tilling L., Townsend S., and David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 26 2 (2006) 55-62
20. Suarez-Almazor M.E., Belsek E., Shea B., et al. Methotrexate for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2 (1997) CD000520
21. Whiting-O'Keefe Q.E., Fye K.H., and Sack K.D. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 90 (1991) 711-726
22. Kaplan M.M. Primary biliary cirrhosis. N Engl J Med 335 21 (1996) 1570-1582
23. Tanaka A., Borchers A.T., Ishibiashi H., et al. Genetic and familial considerations of primary biliary cirrhosis. Am J Gastroenterol 95 1 (2001) 8-15
24. Donaldson P., Agarwal K., Craggs A., et al. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. Gut 48 3 (2001) 397-402
25. Berg P.A., Klein R., and Rocken M. Cytokines in primary biliary cirrhosis. Semin Liver Dis 17 (1997) 115-123
26. Jones A., Selby P.J., Viner G., et al. Tumor necrosis factor, cholestatic jaundice and chronic liver disease. Gut 31 (1990) 938-939
27. Pelli N., Floreani A., Torre F., et al. Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumor necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatits C. Clin Exp Immunol 148 1 (2007) 85-89
28. Mullin G.E., Braun-Elwert L., Bergasa N.V., et al. mRNA expression in the liver of patients with primary biliary cirrhosis and chronic hepatitis B. Clin Exp Immunol 105 (1996) 254-259
29. Harada K., Vandewater J., Leung P.S.C., et al. In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset. Hepatology 25 4 (1997) 791-796
30. Morland C.M., Fear J., Mcnab G., et al. Promotyion of leukocytye transendothelial cell migration by chemokines derived from human biliary epithelial cells in vitro. Proc Assoc Am Physicians 109 4 (1997) 372-382
31. Bjorkland A., Festin R., Mendel-Hrtvig I., et al. Blood and liver infiltrating lymphocytes in primary biliary cirrhosis: Increased in activated T and natural killer cells and recruitment of primed memory T cells. Hepatology 13 (1991) 1106
32. Yeaman S.J., Kirby J.A., and Jones D.E.J. Autoreactive responses to pyruvate dehydrogenase complex in the pathogenesis of primary biliary cirrhosis. Immunol Rev 174 (2000) 238-249
33. Isse K., Harada K., Sato Y., et al. Characterization of biliary intra-epithelial lymphocytes at different anatomic levels of intrahepatic bile ducts under normal and pathologic conditions: numbers of CD4 + CD28- intra-epitheliual lymphocytes are increased in primary biliary cirrhosis. Pathol Int 56 (2006) 17-24
34. Furtwaengler F.C.K., Nepormuceno R.R., Martinez O.M., et al. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver 21 (2001) 272-279
35. Kita H., Naidenko O.V., Kronenberg M., et al. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 123 (2002) 1031-1043
36. Lan R.V., Cheng C., Lian Z.X., et al. Liver targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology 43 (2006) 729-737
37. Wong G., Law F.M., Wong V., et al. Heath-related quality of life in Chinese patients with primary biliary cirrhosis. J Gastroenterol Hepatol (2007) epub ahead of print
38. Heathcote J. AASLD practice guidelines. Management of primary biliary cirrhosis. Hepatology 31 (2000) 1005-1013
39. Pares A., Cabellaria L., and Rhodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastro 130 (2006) 715-720
40. Setchell K.D.R., Rodrigues C.M.P., and Clerici C. Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastro 112 (1997) 226-235
41. Capechot C., Carrat F., Bonnand A.M., et al. The effect of ursodeoxycholic acid on liver fibrosis in primary biliary cirrhosis. Hepatology 32 (2000) 1196-1199
42. Jackson H., Solaymani-Dodaran M., Card T.R., et al. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology (2007) (ahead of print)
43. Kaplan M.M. Sustained remission of primary biliary cirrhosis with methotrexate. [abstract]. Gastro S108 (1995) A1094
44. Kaplan M.M., and Knox T.A. Treatmentof primary biliary cirrhosis with low-dose weekly methotrexate. Gastro 101 (1991) 1332-1338
45. Bonis P., and Kaplan M.M. Methotrexate improves biochemical test in patients with primary biliary cirrhosis who respond incompletely to ursodeoxycholic acid. Gastro 117 2 (1999) 395-399
46. Kaplan M., Cheung S., Price L.L., et al. A randomized controlled trial of colchicines plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten year results. Hepatology 39 (2004) 915-923
47. Lindor K.D., Dickson R., Jorgensen R.A., et al. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the result of a pilot study. Hepatology 22 (1995) 1158-1162
48. Van Steenbergen W., Sciot R., Van Euken P., et al. Combined treatment with methotrexate and ursodeoxycholic acid in non-cirrhotic primary biliary cirrhosis. Acta Clin Belg 51 (1996) 8-18
49. Copaci I., Micu L., and Cojocaru L. Ursodeoxycholic acid and methotrexate for primary biliary cirrhosis. [abstract]. J Hepatol 34 1 (2001) 59
50. Gonzalez-Koch A., Brahm J., Antezana C., et al. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone. J Hepatol 27 1 (1997) 143-149
51. Combes B., Emerson S.E., Flye N., et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 42 5 (2005) 1184-1193
52. Bach N., Bodian C., Bodenheimer H., et al. Methotrexate therapy for primary biliary cirrhosis. Am J Gastroenterol 98 1 (2003) 187-193
53. Poupon R. Trials in primary biliary cirrhosis: need for the right drugs at the right time. Hepatology 39 4 (2004) 900-902
54. Hendrickse M.T., Rigney E., Giaffer M.H., et al. Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo controlled trial. Gastro 117 (1999) 400-407
55. Gong Y., and Gluud C. Methotrexate for primary biliary cirrhosis. Cochrane Database Syst Rev 3 (2005) CD004385
56. Huet P., Deslauriers J., Tran A., et al. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. Am J Gastroenterol 95 3 (2000) 760-767
57. Goulis J., Leandro G., and Burroughs A.K. Randomized controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 354 (1999) 1053-1060
58. Wolfhagen F.H.J., Sternieri E., Hop W.C.J., et al. Oral natrexone treatment for cholestastic pruritus: a double blind, placebo controlled study. Gastroenterology 113 (1997) 1264-1269
59. Ghent C.N., and Carruthers G. Treatment of pruritus in primary biliary cirrhosis with rifampin. Gastroenterology 94 (1988) 488-493
60. Bergassa N.V. The treatment of the pruritus of cholestasis. Curr Treat Options Gastroenterol 7 6 (2004) 501-508
61. Maddrey W., and van Thiel D.H. Liver transplantation: an overview. Hepatology 8 (1998) 948-959
62. Jones D.E.J., Bhala N., Burt J., et al. Four year follow-up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut 55 (2006) 536-541
63. Swain M.G. Fatigue in liver disease: pathophysiology and clinical management. Can J Gastroenterol 20 (2006) 181-188
64. Milkiewicz P., and Heathcote E.J. Fatigue in chronic cholestasis. Gut 53 (2004) 475-477
65. Bergasa N.V., Jones E.A., Kleiner D.E., et al. Pilot study of low dose oral methotrexate treatment for primary biliary cirrhosis. Am J Gastroenterol 91 2 (1996) 295-299
66. Buscher H.P., Zietzschmann Y., and Gerok W. Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone. J Hepatol 18 1 (1993) 9-14
67. Babatin M.A., Sanai F.M., and Swain M.G. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy. Aliment Pharmacol Ther 24 (2006) 813-820
68. Swain M.G., Beck P., Rioux K., et al. Augmented interleukin-1β-induced depression of locomoter activity in cholestatic rats. Hepatology 28 (1998) 1561-1565
69. Swain M.G. Molecular pathophysiology of fatigue and pruritus. In: Trauiner M., and Jansen P.L. (Eds). The molecular pathogenesis of cholestasis (2003), Academic/Plenum Publishers, London
70. Davis H., Olson L., and Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev 2 (2000) CD000391
71. Bambha K., Kim W.R., Talwalker J., et al. Incidence, clinical spectrum and outcome of primary sclerosing cholangitis in a United States community. Gastro 125 (2003) 1364-1369
72. O'Mahony C.A., and Vierling J.M. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis 26 1 (2006) 3-21
73. Bo X., Broome U., Remberger M., et al. Tumor necrosis factor-alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. Gut 49 (2001) 131-141
74. Aoki C.A., Bowlus C.L., and Gershwin M.E. The immunobiology of primary sclerosing cholangitis. Autoimmun Rev 4 (2005) 137-143
75. LaRusso N.F., Shneider B.L., Black D., et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology 44 (2006) 746-764
76. Michell S.A., Bansl D.S., Hunt N., et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastro 121 (2001) 900-907
77. Harnois D.M., Angulo P., Jorgenson R.A., et al. High-dose ursodeoxycholic acid as therapy for primary sclerosing cholagitis. Am J Gastroenterol 96 (2001) 1558-1562
78. Olsson R., Bober K.M., Schaffalitsky de Muckadell O., et al. High dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5 year, multicenter, randomized controlled trial. Gastro 129 (2005) 1464-1472
79. Lindor K.D., Wiesner K.H., Colwell L.J., et al. The combination of prednisone and colchicines in patients with primary sclerosing cholangitis. Am J Gastroenterol 86 (1991) 57-61
80. Talkwalkar J.A., Angulo P., Keach J.C., et al. Mycophenylate mofetil for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 100 2 (2005) 308-312
81. Olsson R., Broome U., Danielsson A., et al. Colchicine treatment of primary sclerosing cholangitis. Gastro 108 (1995) 1199-1203
82. Van Thie D.H., Carroll P., Abu-Elmagd K., et al. Tacrolimus, a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 90 3 (1995) 455-459
83. Kaplan M.M., Arora S., and Pincus S.H. Primary sclerosing cholangitis and low-dose oral pulse methotrexate therapy. Clinical and histologic response. Ann Intern Med 106 (1987) 231-235
84. Knox T.A., and Kaplan M.M. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastro 106 (1994) 494-499
85. Lindor K.D., Jorgensen R.A., Anderson M.L., et al. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am J Gastroenterol 91 3 (1996) 511-515
86. Duerksen D.R., Blondell-Hill E., and Bailey R.J. Pneumocytis carinii pneumonia complicating methotrexate treatment of primary sclerosing cholangitis. Am J Gastroenterol 90 10 (1995) 1886-1887